Koyfin Home > Directory > Health Care > Kindred Biosciences > Net Debt / (EBITDA-CAPEX)

Kindred Biosciences Net Debt / (EBITDA-CAPEX) Chart (KIN)

Kindred Biosciences annual/quarterly Net Debt / (EBITDA-CAPEX) from 2013 to 2020.
  • Kindred Biosciences Net Debt / (EBITDA-CAPEX) for the quarter ending June 06, 2020 was $1m a -18.14% decrease of 0m year over year
  • Kindred Biosciences Net Debt / (EBITDA-CAPEX) for the last 12 months ending June 06, 2020 was $1m a -33.07% decrease of 0m year over year
  • Kindred Biosciences Annual Net Debt / (EBITDA-CAPEX) for 2019 was $1m a -58.58% decrease of 0m from 2018
  • Kindred Biosciences Annual Net Debt / (EBITDA-CAPEX) for 2018 was $1m a -90.15% decrease of -1m from 2017
  • Kindred Biosciences Annual Net Debt / (EBITDA-CAPEX) for 2017 was $2m a -13.16% decrease of 0m from 2016
Other Ratios Metrics:
  • Kindred Biosciences Other Liabilities for the quarter ending December 12, 2018 was $0m a -18.09% decrease of 0m year over year
View Chart On Koyfin

Quarterly KIN Net Debt / (EBITDA-CAPEX) Data

06/2020$1m
03/2020$0m
12/2019$1m
09/2019$1m
06/2019$1m
03/2019$1m
12/2018$1m
09/2018$1m
06/2018$2m
03/2018$2m

Annual KIN Net Debt / (EBITDA-CAPEX) Data

2019$1m
2018$1m
2017$2m
2016$2m
2015$3m
2014$4m
2013$15m